XML 59 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Other Costs (Tables)
 12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Other Costs by Segment Restructuring and other costs by segment are as follows:
(In millions)202220212020
Life Sciences Solutions
$30 $129 $34 
Analytical Instruments
1 6 26 
Specialty Diagnostics
68 18 9 
Laboratory Products and Biopharma Services
12 35 23 
Corporate
3 9 7 
$114 $197 $99 
Schedule of the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2019$34 
Net restructuring charges incurred in 2020 (b)
51 
Payments
(57)
Currency translation
(7)
Balance at December 31, 202021 
Net restructuring charges incurred in 2021 (c)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (d)
68 
Payments
(44)
Balance at December 31, 2022$41 
(a)The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
(b)Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities.
(c)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(d)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.